Kytril (Granisetron)

Granisetron works by selectively antagonizing serotonin 5‑HT3 receptors located in the chemoreceptor trigger zone of the brain and in the gastrointestinal tract. By preventing serotonin from binding to these receptors, it interrupts the neural pathways that initiate the vomiting response, thereby reducing both acute and delayed emesis.

The dosage of Kytril is determined by the prescribing clinician based on the specific clinical situation, such as the type of chemotherapy or the surgical procedure. The prescriber will consider factors like patient weight, renal and hepatic function, and the emetogenic potential of the treatment when setting the appropriate dose.

Safety data for granisetron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile for each individual case before prescribing Kytril to pregnant or nursing patients.

To order Kytril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Kytril (granisetron) belongs to the 5‑HT3 antagonist class, similar to ondansetron and palonosetron. Compared with older agents, granisetron has a longer half‑life and a lower incidence of drug‑induced QT prolongation. Choice of antiemetic often depends on the specific chemotherapy regimen, patient tolerance, and physician preference.

Kytril should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging to protect it from moisture and light. Do not freeze the solution, and ensure that the vial is kept upright to avoid agitation of the contents.

Kytril is administered intravenously. The healthcare professional will dilute the injectable solution according to the prescribing information and deliver it over a short period, typically as a single dose before chemotherapy or surgery. Administration is performed under medical supervision to monitor for any immediate reactions.

The most serious risks include severe allergic reactions such as anaphylaxis, cardiac arrhythmias including QT interval prolongation, and profound hypotension. Patients with a history of cardiac disease or electrolyte disturbances should be monitored closely, and any signs of an allergic response require immediate medical intervention.

Kytril should be avoided in patients with known hypersensitivity to granisetron or any component of the formulation. Caution is advised for individuals with a history of prolonged QT interval, severe cardiac conduction disorders, or significant hepatic impairment. In such cases, alternative antiemetic strategies may be considered.